Is INmune Bio, Inc. (INMB) a Buy, Sell, or Hold?
NASDAQ : INMB
INmune Bio, Inc.
$1.75 USD
-$0.02 (-1.13%)
- Volume
- 225.33K
- Average Volume
- 781.08K
- Market Capitalization
- $46.52M
- P/E Ratio
- -1.04
- Dividend Yield
- 0.00%
- Price Target
- $22.00
- Year High
- $2.96
- Year Low
- $1.09
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.24
Company Overview
NASDAQ
David J. Moss
Biotechnology
Healthcare
INMB
21
US
USD
Liquidity Metrics
0.08
4.24
4.24
3.96
0.00
Sales & Valuation
$50000
0.00
2.37
-2.24
-0.78
Profitability
-$1.86
-$45.93M
0.00%
0.00%
-170.86%
-161.13%
P/E Metrics
-1.04
-1.17
-1.17
Analyst Price Target & Rating
$22.00
$22.00
$22.00
2/5
9 Analysts
-92.05%
Financial Health Scores
-9.51
2/9
$17.43M
$25.82M
$6.19M
-$25.2M
Key Metrics (TTM)
$26.68M
0.00
-1.06
4.24
-170.86%
-204.84%
-89.42%
-44.66%
-15746 days
Company Executives
| Name | Title |
|---|---|
| Mark William Lowdell | Chief Scientific Officer & Chief Manufacturing Officer |
| Daniel Frederick Carlson | Head of Investor Relations |
| Joshua S. Schoonover | General Counsel |
| Cory Randall Ellspermann | Interim Chief Financial Officer |
| David J. Moss | President, Chief Executive Officer, Treasurer, Secretary & Director |
Poll Results
No votes yet today — be the first to share your view!
About INmune Bio, Inc. (NASDAQ:INMB) Stock
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio ... holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
2026-07-31 07:00:00
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference call on Thursday, August 6th, 2026 at 4:30pm EDT to discuss results for its quarter ended June 30, 2026 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
2026-07-31 07:00:00
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference call on Thursday, August 6th, 2026 at 4:30pm EDT to discuss results for its quarter ended June 30, 2026 and to provide a corporate update.
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
2026-07-31 07:00:00
BOCA RATON, Fla. , July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate from Australia of approximately $4.
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
2026-07-31 07:00:00
BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate from Australia of approximately $4.2 million. This rebate is in addition to approximately $0.4 million of rebate from the United Kingdom during June 2026. After adjusting second-quarter operating cash flows to exclude the approximately $0.4 million rebate received during the quarter, the combined rebate proceeds exceeded the Company's net cash used in operating activities during the quarter. The rebates strengthen the Company's balance sheet and extend its cash runway as INmune Bio advances CORDStrom™ (Ebstrocel™) toward regulatory filings.
2026-07-30 07:00:00
Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities
2026-07-20 07:00:00
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply. Company Expresses Support for MHRA Draft Rare Disease Therapies Regulatory Framework BOCA RATON, Fla, July 20, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced a significant manufacturing milestone for its CORDStrom™ platform.
2026-07-15 07:00:00
The study points to soluble TNF as a key biological link between head injury and Alzheimer's disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes. Boca Raton, FL, July 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc.
2026-07-15 07:00:00
The study points to soluble TNF as a key biological link between head injury and Alzheimer's disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes.
Frequently Asked Questions
-
What is the current INmune Bio, Inc. (INMB) stock price?
-
INmune Bio, Inc.(NASDAQ:INMB) stock price is $1.75 in the last trading session. During the trading session, INMB stock reached the peak price of $2.96 while $1.09 was the lowest point it dropped to. The percentage change in INMB stock occurred in the recent session was --1.13% while the dollar amount for the price change in INMB stock was -$0.02.
-
INMB's industry and sector of operation?
-
The NASDAQ listed INMB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of INMB?
-
Mark William Lowdell | Chief Scientific Officer & Chief Manufacturing Officer
Daniel Frederick Carlson | Head of Investor Relations
Joshua S. Schoonover | General Counsel
Cory Randall Ellspermann | Interim Chief Financial Officer
David J. Moss | President, Chief Executive Officer, Treasurer, Secretary & Director -
How many employees does INMB have?
-
Number of INMB employees currently stands at 21. INMB operates from 225 NE Mizner Boulevard, Boca Raton, FL 33432, US.
-
Link for INMB official website?
-
Official Website of INMB is: https://www.inmunebio.com
-
How do I contact INMB?
-
INMB could be contacted at phone #858 964 3720 and can also be accessed through its website. INMB operates from 225 NE Mizner Boulevard, Boca Raton, FL 33432, US.
-
How many shares of INMB are traded daily?
-
The average number of INMB shares traded daily for last 3 months was 781.08K.
-
What is the market cap of INMB currently?
-
The market value of INMB currently stands at $46.52M with its latest stock price at $1.75